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Introduction
Polycystic ovary syndrome (PCOS) is the commonest hyperandro-
genic and dysmetabolic disorder which affects 6–10 % of women 
of child-bearing age [1, 2]. Subjects with PCOS have significantly 
higher rates of insulin resistance, impaired glucose tolerance, dys-
lipidemia, and metabolic syndrome than those subjects without 
the disease [3]. Insulin resistance and elevated lipid profiles occur 
in 50–75 % and 70 % of women with PCOS, respectively [4, 5]. Insu-
lin resistance and dyslipidemia are central components of meta-
bolic syndrome, and a significant risk factor for type 2 diabetes mel-
litus (T2DM) and cardiovascular disease (CVD) [6].
Recently, the role of vitamins such as vitamin D and minerals 
including calcium, selenium and zinc in the developing of many 
diseases including PCOS has been evaluated [7, 8]. We have previ-
ously shown that supplementation with 1 000 mg/day calcium plus 
50 000 IU/week vitamin D for 8 weeks among vitamin D-deficient 
subjects with PCOS had beneficial effects on markers of insulin me-
tabolism, serum triglycerides and VLDL-cholesterol levels, but did 
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Abstr Act
Background Data on the effects of calcium, vitamins D and K co-sup-
plementation on markers of insulin metabolism and lipid profiles among 
vitamin D-deficient women with polycystic ovary syndrome (PCOS) are 
scarce.
Objective This study was done to determine the effects of calcium, 
vitamins D and K co-supplementation on markers of insulin metabolism 
and lipid profiles in vitamin D-deficient women with PCOS.
Methods This randomized double-blind, placebo-controlled trial was 
conducted among 55 vitamin D-deficient women diagnosed with PCOS 
aged 18–40 years old. Subjects were randomly assigned into 2 groups 
to intake either 500 mg calcium, 200 IU vitamin D and 90 µg vitamin K 
supplements (n = 28) or placebo (n = 27) twice a day for 8 weeks.
Results After the 8-week intervention, compared with the placebo, 
joint calcium, vitamins D and K supplementation resulted in significant 
decreases in serum insulin concentrations ( − 1.9 ± 3.5 vs.  + 1.8 ± 6.6 µIU/
mL, P = 0.01), homeostasis model of assessment-estimated insulin re-
sistance ( − 0.4 ± 0.7 vs.  + 0.4 ± 1.4, P = 0.01), homeostasis model of 
assessment-estimated b cell function ( − 7.9 ± 14.7 vs.  + 7.0 ± 30.3, 
P = 0.02) and a significant increase in quantitative insulin sensitivity 
check index ( + 0.01 ± 0.01 vs.  − 0.008 ± 0.03, P = 0.01). In addition, sig-
ni f icant  decreases  in  serum tr ig lycer ides  (  −  23.4  ±  71.3 
vs.  + 9.9 ± 39.5 mg/dL, P = 0.03) and VLDL-cholesterol levels ( − 4.7 ± 14.3 
vs.  + 2.0 ± 7.9 mg/dL, P = 0.03) was observed following supplementation 
with combined calcium, vitamins D and K compared with the placebo.
Conclusion Overall, calcium, vitamins D and K co-supplementation for 
8 weeks among vitamin D-deficient women with PCOS had beneficial 
effects on markers of insulin metabolism, serum triglycerides and VLDL-
cholesterol levels.
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not influence fasting plasma glucose and other lipid profiles [9]. In 
addition, vitamins D, K and calcium co-supplementation for 12 
weeks among diabetic patients with coronary heart disease (CHD) 
improved markers of insulin metabolism and HDL-cholesterol lev-
els, but unchanged other lipid profiles [10]. However, vitamin D 
and calcium co-supplementation for 6 months did not affect insu-
lin sensitivity, insulin secretion and β-cell function among multi-
ethnic adults with low vitamin D status at risk of T2DM [11]. More-
over, vitamin K administration for 36 months at a dosage of 500 µg/
day decreased insulin resistance among older men [12].
Vitamins D, K and calcium supplementation may improve met-
abolic status through their effects on up-regulation of the insulin 
receptor genes [13], the regulation of insulin secretion from the 
pancreatic beta-cell [14], and the enhancement of β-cell prolifera-
tion and adiponectin expression [15]. However, beneficial effects 
of combined vitamin D and calcium on markers of insulin metabo-
lism and lipid profiles in PCOS subjects [9] and patients with T2DM 
[16] have previously reported, data on the effect of calcium, vita-
mins D and K co-supplementation on markers of insulin metabo-
lism and lipid profiles among vitamin D-deficient subjects with PCOS 
are scarce. This study aimed to determine the effects of calcium, vi-
tamins D and K co-supplementation on markers of insulin metabo-
lism and lipid profiles in vitamin D-deficient subjects with PCOS.
Subjects and Methods
Trial design
This was an 8-week randomized, double-blind, placebo-controlled 
clinical trial.
Participants
Participants of this study were 55 PCOS women which were select-
ed from the endocrinology and gynecology services of Iran Univer-
sity of Medical sciences (IUMS) from July 2016 to August 2016 at 
summer season. Diagnosis of PCOS was performed according to the 
Rotterdam criteria [17]: those with the 2 of the following criteria 
were considered as having PCOS: oligo- and/or anovulation  (defined 
as delayed menses > 35 days or < 8 spontaneous hemorrhagic epi-
sodes/year), clinical (hirsutism using modified Ferriman-Gallwey 
score of ≥ 8) and/or biochemical signs of hyperandrogenism and 
polycystic ovaries (12 or more follicles in each ovary measuring 
2–9 mm in diameter, and/or increased ovarian volume > 10 ml3).
Ethics statements
This research was done in accordance with the Declaration of Hel-
sinki and Good Clinical Practice guidelines, and written informed 
consent was obtained from all subjects prior to the intervention. 
The current study was approved by the ethics committee of IUMS 
and was registered in the Iranian website for registration of clinical 
trials (http://www.irct.ir: IRCT201608115623N87).
Inclusion and exclusion criteria
Vitamin D-deficient ( < 20 ng/mL) subjects with PCOS aged 18–40 
years with phenotypes A (oligo-anovulation + hyperandrogen-
ism + polycystic ovary morphology) and D (oligo-anovulation + pol-
ycystic ovary morphology) were included in the study. Exclusion cri-
teria were pregnancy, adrenal gland disorders and/or other endo-
crine diseases and hormonal treatments in the previous 6 months.
Study design
At first, persons were randomly divided into 2 groups by random 
permuted blocks to intake either 500 mg calcium, 200 IU vitamin 
D plus 90 µg vitamin K supplements (n = 28) or placebo (n = 27) 
twice a day for 8 weeks. The randomized allocation sequence, en-
rolling subjects and assigning patients to the groups were conduct-
ed as blindness by a trained midwife. Calcium, vitamins D and K 
capsules and its placebos (cellulose) were provided by Arian Sala-
mt Sina (Tehran, Iran) and Barij Essence Pharmaceutical Company 
(Kashan, Iran), respectively. At baseline, subjects were asked not to 
alter their routine physical activity or usual dietary intakes through-
out the study and not to take any antioxidants supplements, anti-
inflammatory medications and other medications that might af-
fect their reproductive physiology during the 8-wk intervention 
[18]. All persons were recorded 3-day dietary records and 3 physi-
cal activity records at baseline, weeks 2, 4, 6 and 8 of intervention. 
To compute daily macro- and micro-nutrient intakes of persons ac-
cording to 3-day food diaries, we used Nutritionist IV software (First 
Databank, San Bruno, CA) adjusted for Iranian foods.
Treatment adherence
Every 2 weeks, subjects were taken enough supplements and pla-
cebos and were instructed to return all unused supplements and 
placebos at each visit. Compliance to the take of calcium, vitamins 
D and K supplements and placebos was checked through asking 
participants to bring the medication containers and receiving short 
messages on their cell phones each day.
Assessment of anthropometric measures
All patients were evaluated at the study start on the third day of a 
spontaneous or progesterone-induced menstrual cycle [18]. An-
thropometric measures including height, weight (Seca, Hamburg, 
Germany) and body mass index (BMI) were quantified in the onset 
and the end of the study.
Assessment of outcomes
The primary outcome measurements were HOMA-IR in the current 
study. The secondary outcome measurements were lipid profiles.
Biochemical assessment
12-h fasting blood samples were taken by venipuncture at weeks 0 
and 8 at the IUMS reference laboratory. Blood samples were taken 
based on a standard protocol and immediately centrifuged (Hettich 
D-78532, Tuttlingen, Germany). Then, the samples were stored 
at  − 80 °C until analysis at the IUMS reference laboratory. To evaluate 
fasting plasma glucose (FPG), serum triglycerides, VLDL-, total-, LDL- 
and HDL-cholesterol concentrations, we used available kits (Pars 
Azmun, Tehran, Iran) with enzymatic method. All inter- and intra-as-
say CVs for FPG and lipid fractions were lower than 5 %. Circulating 
concentrations of serum insulin were assessed using ELISA kit 
(Monobind, California, USA) with the intra- and inter-assay CVs 3.0 
and 4.8 %, respectively. HOMA-IR, homeostatic model assessment for 
B-cell function (HOMA-B) and the quantitative  insulin sensitivity check 
index (QUICKI) were calculated according to suggested formulas [19].
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Sample size
To determine the sample size, we used a randomized clinical trial 
sample size formula where type one (α) and type 2 errors (β) were 
0.05 and 0.20 (power = 80 %), respectively. Based on a previous 
study [10], we used 1.2 as SD and 1.0 as the difference in mean (d) 
of HOMA-IR as primary variable. Based on this, we needed 25 sub-
jects in per group. Assuming a dropout of 5 persons in each group, 
we calculated to have 30 persons per group.
Statistical methods
To assess normal distribution of variables, we conducted the Kol-
mogrov-Smirnov test. To detect differences in the general charac-
teristics, and daily macro- and micro-nutrient intakes between the 
2 groups, we used independent samples Student’s t test. To dem-
onstrate the effects of calcium, vitamins D and K co-supplementa-
tion on glucose metabolism and lipid fractions, one-way repeated-
measures ANOVA was used. To control the effect of confounders 
including baseline values of biochemical parameters, age and BMI 
at baseline, we applied ANCOVA. A P-value < 0.05 was considered 
statistically significant. All statistical analyses were conducted using 
the Statistical Package for Social Science version 18 (SPSS Inc., 
 Chicago, Illinois, USA).
Results
At the screening visit, 850 participants were screened for PCOS. 
760 participants of the 850 screened participants were excluded 
from the first visit due to not having PCOS. Thus, at baseline, we in-
vited 90 women with PCOS according to Rotterdam criteria; how-
ever, 30 participants were excluded from the study because of not 
living in Tehran (n = 12) and not having inclusion criteria (n = 18) 
(▶Fig. 1). Among participants in the calcium, vitamins D and K 
group, 2 participants (withdrawn due to personal reasons in the 
second month) and in the placebo group, 3 participants [withdrawn 
due to personal reasons (2 participants in the second month and 1 
participant in the third month)] did not complete the trial. Finally, 
55 participants [vitamins D and K co-supplements (n = 28) and pla-
cebo (n = 27)] completed the trial. On average, the rate of compli-
ance in this trial was high, such that more than 90 % of tablets were 
taken throughout the study in both groups. No adverse events were 
reported following consumption of calcium, vitamins D and K co-
supplements in participants with PCOS throughout the study.
Mean age, baseline weight and BMI, and end-of-trial weight and 
BMI were not significantly different between the 2 groups (▶table 1).
Based on the 3-day dietary records taken throughout the inter-
vention, no significant change was observed between the 2 groups 
in terms of macro- and micro-nutrient intakes (Data not shown).
After the 8-week intervention, compared with the placebo, joint 
calcium, vitamins D and K supplementation resulted in significant 
decreases in serum insul in concentrations (− 1.9 ± 3.5 
vs.  + 1.8 ± 6.6 µIU/mL, P = 0.01), HOMA-IR ( − 0.4 ± 0.7 vs. + 0.4 ± 1.4, P = 
0.01), HOMA-B ( − 7.9 ± 14.7 vs. + 7.0 ± 30.3, P = 0.02) and a signifi cant 
increase in QUICKI (+ 0.01 ± 0.01 vs. − 0.008 ± 0.03, P = 0.01) 
(▶table 2). In addition, significant decreases in serum triglycerides 
( − 23.4 ± 71.3 vs.  + 9.9 ± 39.5 mg/dL, P = 0.03) and VLDL-cholesterol 
levels ( − 4.7 ± 14.3 vs.  + 2.0 ± 7.9 mg/dL, P = 0.03) was observed follow-
ing supplementation with combined calcium, vitamins D and K 
compared with the placebo. We did not see any significant change 
in FPG and other lipid profiles.
When we adjusted the analysis for baseline values of biochemi-
cal values, age and baseline BMI, QUICKI (P = 0.06) became non-
significant, and other findings did not alter (▶table 3).
Randomized (n = 60)
Allocated to placebo (n = 30)
Lost to follow-up due to
personal reasons (n = 3)
Analyzed (n = 27)
Allocated to intervention (n = 30)
Lost to follow-up due to personal
reasons (n = 2)
Analyzed (n = 28)
Assessed for eligibility (n = 90)
Excluded (n = 30)
– Not meeting inclusion criteria (n = 18)
– Not living in Tehran (n = 12)
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llm
en
t
Al
lo
ca
tio
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w
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▶Fig. 1 Summary of patient flow diagram.
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Discussion
We found that calcium, vitamins D and K co-supplementation 
among vitamin D-deficient subjects with PCOS for 8 weeks im-
proved markers of insulin metabolism, serum triglycerides and 
VLDL-cholesterol levels compared with the placebo, but did not af-
fect FPG and other lipid profiles.
There have been many studies indicating a significant relation 
between vitamin D concentration and beta cell function [20] and 
plasma glucose levels [21]. In addition, there is few evidence that 
low 25-hydroxyvitamin D concentrations are related to hyperinsu-
linemia in women with PCOS [22]; however, the findings are incon-
sistent. In line with our study, Tabesh et al. [16] found that supple-
mentation with 1 000 mg/day calcium plus 50 000 IU/week vitamin 
D among patients with T2DM after 12 weeks improved glucose 
metabolism. Vitamin D supplementation (20 000 IU weekly for 24 
weeks) also improved glucose metabolism and menstrual frequen-
cy in PCOS women [23]. Vitamin D and calcium co-supplementation 
for 4 months among women with PCOS resulted in a better out-
come in a variety of PCOS symptoms including menstrual regular-
ity and ovulation [24]. Furthermore, Pittas et al. [25] observed that 
co-supplementation with vitamin D and calcium for 3 years im-
proved glucose homeostasis parameters in adults with normal glu-
cose tolerance. In another study, vitamin K administration for 36 
months at a dosage of 500 µg/day decreased HOMA-IR among 
older men, but it could not affect older women [12]. However, Pal 
et al. [26] observed no significant effect on glucose metabolism 
following supplementation with vitamin D and calcium in over-
weight vitamin D-deficient women with PCOS after 3 months. Pre-
vious studies have shown that impaired insulin metabolism are 
 frequent findings in PCOS patients, and these traits have cause-
consequence relationships with increased risk of CVD [27], T2DM 
[28] and dyslipidemia [29]. Therefore, based on our findings, we 
concluded that joint vitamins D-K-calcium supplementation due 
to improvement in insulin metabolism might help women with 
PCOS to control their insulin resistance. Vitamins D, K and calcium 
intake may improve markers of insulin metabolism through their 
effects on up-regulation of the insulin receptor genes [13], the reg-
ulation of insulin secretion from the pancreatic beta-cell [14], the 
enhancement of β-cell proliferation, adiponectin expression [15] 
and suppression of inflammation [30].
So far, several intervention studies, with divergent findings, have 
examined the effects of vitamin D or calcium administration on lipid 
concentrations [31, 32]. Major et al. [33] found that co-supplemen-
tation with 1 200 mg/day calcium and 400 IU vitamin D in over-
weight or obese women for 15 weeks improved lipid profiles. Un-
like, other researchers [13, 14] did not find any significant effect of 
calcium-vitamin D supplementation on lipid profiles among post-
menopausal women for 5 years [34] and 7 years [35]. Dyslipidemia 
is the most common metabolic abnormality in subjects with PCOS, 
although the type and extent of the derangement has been varia-
ble [36]. Elevated lipid profiles in subjects with PCOS would result 
▶table 1 General characteristics of study participants.
Placebo 
group 
(n = 27)
calcium, 
vitamins D and 
K group (n = 28)
P1
Age (y) 23.3 ± 3.4 23.5 ± 4.2 0.88
Height (cm) 163.0 ± 6.0 162.2 ± 4.2 0.57
Weight at study 
baseline (kg)
64.3 ± 8.5 63.8 ± 12.5 0.85
Weight at 
end-of-trial (kg)
64.1 ± 8.1 63.7 ± 12.3 0.89
Weight change (kg)  − 0.2 ± 1.6  − 0.1 ± 1.0 0.63
BMI at study 
baseline (kg/m2)
24.3 ± 3.9 24.2 ± 4.8 0.95
BMI at end-of-trial  
(kg/m2)
24.2 ± 3.7 24.2 ± 4.7 0.99
BMI change  
(kg/m2)
 − 0.1 ± 0.6  − 0.03 ± 0.4 0.58
Data are means ± SDs; 1 Obtained from independent t test
▶table 2  The effect of calcium, vitamins D and K and calcium co-supplementation on markers of insulin metabolism and lipid profiles in PCOS patients1.
Placebo group (n = 27) calcium, vitamins D and K group (n = 28) P2
baseline End-of-trial change baseline End-of-trial change
Vitamin D (ng/mL) 14.8 ± 3.9 14.5 ± 5.0  − 0.3 ± 4.3 14.7 ± 2.5 20.0 ± 3.0 5.3 ± 1.9  < 0.001
Calcium (mg/dL) 9.4 ± 0.6 9.3 ± 0.7  − 0.1 ± 0.3 9.3 ± 0.5 9.5 ± 0.5 0.2 ± 0.5 0.02
FPG (mg/dL) 83.6 ± 13.0 88.6 ± 20.5 5.0 ± 19.7 84.2 ± 6.9 84.5 ± 6.7 2.1 ± 7.5 0.46
Insulin (μIU/mL) 10.4 ± 5.3 12.2 ± 6.1 1.8 ± 6.6 11.8 ± 4.7 9.9 ± 3.7  − 1.9 ± 3.5 0.01
HOMA-IR 2.1 ± 1.0 2.5 ± 1.3 0.4 ± 1.4 2.4 ± 1.0 2.0 ± 0.8  − 0.4 ± 0.7 0.01
HOMA-B 44.7 ± 30.9 51.7 ± 30.0 7.0 ± 30.3 47.9 ± 19.9 40.0 ± 15.9  − 7.9 ± 14.7 0.02
QUICKI 0.34 ± 0.02 0.34 ± 0.02  − 0.008 ± 0.03 0.33 ± 0.02 0.34 ± 0.01 0.007 ± 0.01 0.01
Triglycerides (mg/dL) 108.5 ± 49.6 118.4 ± 43.1 9.9 ± 39.5 107.1 ± 90.7 83.7 ± 41.1  − 23.4 ± 71.3 0.03
VLDL-cholesterol (mg/dL) 21.7 ± 9.9 23.7 ± 8.6 2.0 ± 7.9 21.4 ± 18.1 16.7 ± 8.2  − 4.7 ± 14.3 0.03
Total cholesterol (mg/dL) 159.0 ± 36.9 159.1 ± 30.5 0.1 ± 31.2 151.6 ± 30.9 144.7 ± 27.2  − 6.9 ± 25.8 0.36
LDL-cholesterol (mg/dL) 82.4 ± 29.4 77.2 ± 28.3  − 5.2 ± 32.9 74.4 ± 24.1 70.6 ± 21.2  − 3.8 ± 20.9 0.85
HDL-cholesterol (mg/dL) 55.0 ± 11.9 58.3 ± 18.4 3.3 ± 14.3 55.7 ± 9.8 57.4 ± 8.5 1.7 ± 5.1 0.55
1  All values are means ± SDs; 2 Obtained from repeated measures ANOVA test; FPG, fasting plasma glucose; HOMA-IR, homeostasis model of 
assessment-estimated insulin resistance; HOMA-B, homeostasis model of assessment-estimated b cell function; QUICKI, quantitative insulin 
sensitivity check index 
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in increased risk of CVD [37]. Several mechanisms can explain the 
beneficial effects of combined calcium-vitamin D supplementation 
on serum triglycerides and VLDL-cholesterol levels. Calcium intake 
might result in reduced absorption of fatty acids and increased fecal 
fatty acid content through formation of insoluble calcium-fatty 
soaps in the gut [38], which in turn decrease serum triglycerides 
and VLDL-cholesterol levels. In addition, increased intracellular cal-
cium in liver results in stimulating microsomal triglycerides trans-
fer protein (MTP), and then causes decreased serum triglycerides 
and VLDL-cholesterol levels [39]. Moreover, vitamin D suppresses 
apo A1 gene expression at the transcriptional levels [40], which may 
result in decreased levels of triglycerides and VLDL-cholesterol.
This trial had some limitations. Due to limited funding, we did 
not evaluate the effects of calcium, vitamins D and K co-supple-
mentation on serum vitamin K concentrations. Another limitation 
was that we did not assess gene expression related to insulin and 
lipid. It must be kept in mind that in the present study, we used the 
dosages of 400 IU vitamin D, 1 000 mg calcium plus 180 µg vitamin 
K per day based on observed beneficial effects of combined vita-
min D, K and calcium supplementation on metabolic profiles in a 
previous study in overweight diabetic patients with CHD [10]. How-
ever, several studies have used higher doses of vitamin D in PCOS 
women [41, 42], we agree that future studies are needed to con-
firm our findings. In addition, our study was relatively of short du-
ration of intervention for sustainable changes in the predefined 
outcome parameters. Long-term interventions might result in 
greater changes in circulating levels of metabolic profiles. It must 
be considered that we had not data about the time of sunlight ex-
posure at baseline, end-of-trial and throughout the intervention. 
Although we believe that this status can affect our findings, this 
should be taken into account in the interpretation of our findings.
Overall, calcium, vitamins D and K co-supplementation for 8 
weeks among vitamin D-deficient women with PCOS had benefi-
cial effects on markers of insulin metabolism, serum triglycerides 
and VLDL-cholesterol levels, but it did not affect fasting plasma glu-
cose and other lipid profiles.
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